SB256
Interim Study (House)(New Title) establishing safety and care requirements for clinician-administered drugs.
Status
Hearing
No upcoming hearing scheduled.
Testimony
3 total submissions
Bill Docket
Refer for Interim Study: MA VV 05/14/2026 HJ 13
HouseMay 14, 2026
Committee Report: Refer for Interim Study 04/29/2026 (Vote 15-0; CC) HC 19 P. 6
HouseMay 01, 2026
Executive Session: 04/29/2026 10:00 am GP 229
HouseApril 22, 2026
Subcommittee Work Session: 04/22/2026 10:00 am GP 229
HouseApril 16, 2026
Public Hearing: 04/07/2026 02:15 pm GP 159
HouseApril 02, 2026
Subcommittee Work Session: 04/08/2026 10:00 am GP 229
HouseApril 01, 2026
Vacated and Referred to Commerce and Consumer Affairs (Rep. Kofalt): MA VV (in recess of) 02/19/2026 HJ 5 P. 127
HouseMarch 02, 2026
Introduced (in recess of) 02/19/2026 and referred to Health, Human Services and Elderly Affairs HJ 5 P. 124
HouseFebruary 26, 2026
Ought to Pass with Amendment #2025-3029s, MA, VV; OT3rdg; 01/07/2026; SJ 1
SenateJanuary 07, 2026
Committee Amendment # 2025-3029s, AA, VV; 01/07/2026; SJ 1
SenateJanuary 07, 2026
Committee Report: Ought to Pass with Amendment # 2025-3029s, 01/07/2026; Vote 5-0; CC; SC 46
SenateOctober 22, 2025
Rereferred to Committee, MA, VV; 03/06/2025; SJ 6
SenateMarch 06, 2025
Committee Report: Rereferred to Committee, 03/06/2025; Vote 5-0; CC; SC 11
SenateFebruary 21, 2025
Hearing: 02/12/2025, Room 101, LOB, 09:15 am; SC 9
SenateFebruary 05, 2025
Introduced 01/09/2025 and Referred to Health and Human Services; SJ 3
SenateJanuary 23, 2025